Lam Research Corporation Announces March Quarter Financial Conference Call
Webcast:
To access the webcast, visit the Investors section of Lam's website at http://www.lamresearch.com and click on the Investors/Investors Overview/Events & Presentations section to view the details.
Replay Information:
A webcast replay will be available on the Lam Research website approximately three hours after the conference call concludes.
About Lam Research
Lam Research Corporation (NASDAQ: LRCX) is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. Lam's equipment and services allow customers to build smaller and better performing devices. In fact, today, nearly every advanced chip is built with Lam technology. We combine superior systems engineering, technology leadership, and a strong values-based culture, with an unwavering commitment to our customers. Lam Research is a FORTUNE 500® company headquartered in Fremont, California, with operations around the globe. Learn more at www.lamresearch.com (LRCX).
IR Contact:
Ram GaneshInvestor Relations(510) 572-1615investor.relations@lamresearch.com
Source: Lam Research Corporation, (Nasdaq: LRCX)
View original content:https://www.prnewswire.com/news-releases/lam-research-corporation-announces-march-quarter-financial-conference-call-302418995.html
SOURCE Lam Research Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Rivian Stock Slips as Morgan Stanley Slashes Price Target to $12
Aug 12 - Rivian (NASDAQ:RIVN) stock dipped about 2.5% Tuesday morning after Morgan Stanley trimmed its price target to $12 from $13 while keeping an Equal-weight rating. Traders reacted to Morgan Stanley's cautious tone on Rivian's upcoming R2 launch and heavy capital needs to compete in autonomy. Rivian trades near $11.69 with a market cap around $14.5 billion and sits down more than 10% year-to-date. Warning! GuruFocus has detected 5 Warning Signs with RIVN. Morgan Stanley said Rivian shows promise in AI-enabled autonomy but expressed reservations about the steering-wheel-equipped R2 and current EV demand headwinds. The bank also noted that Rivian's Volkswagen partnership may steady volatility but could cap upside. Other brokers downgraded pressure: UBS cut its target to $12, DA Davidson to $13, TD Cowen to $13, Piper Sandler to $14, and Stifel to $16, each pointing to margin pressure, tariff effects, or production downtime ahead of R2. Collectively, analysts weigh between the long term potential of Rivian and near term risks of execution. As it gets ready to launch the next batch of vehicles, investors will be eyeing R2 rollout information, margins forecast and cash management by the management. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Why Independent Bank (INDB) Stock Is Trading Up Today
What Happened? Shares of regional banking company Independent Bank (NASDAQ:INDB) jumped 3.8% in the afternoon session after a broad market rally fueled by renewed optimism for a Federal Reserve interest rate cut and a positive development in U.S.-China trade relations. The broader market surge, which particularly benefited the financial sector, is being fueled by two key factors. Firstly, a weaker-than-expected inflation report has boosted investor confidence that the Federal Reserve may cut interest rates, potentially as soon as next month. This prospect of monetary easing creates a favorable environment for economic growth. Secondly, the extension of a U.S.-China tariff truce has reduced concerns about trade disputes, further improving overall market sentiment. This combination of events has led to a "risk-on" atmosphere, encouraging investment in equities. The shares closed the day at $66.89, up 3.9% from previous close. Is now the time to buy Independent Bank? Access our full analysis report here, it's free. What Is The Market Telling Us Independent Bank's shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 11 days ago when the stock dropped 3.2% on the news that a surprisingly weak July jobs report and the announcement of sweeping new tariffs fueled fears of an economic slowdown and an impending interest rate cut. The U.S. economy added just 73,000 jobs in July, the weakest gain in over two years, while the unemployment rate rose to 4.2%. This dismal data significantly increased market expectations for a Federal Reserve interest rate cut, with traders now pricing in an 80% probability of a cut in September. Lower interest rates typically harm bank profitability by compressing their net interest margins—the difference between what they earn on loans and pay on deposits. Compounding these worries, the announcement of new tariffs on imports from 92 countries has sparked fears of a global trade war, which could further dampen economic growth and disrupt supply chains, creating a challenging environment for the banking industry. Independent Bank is up 5.9% since the beginning of the year, but at $66.90 per share, it is still trading 10.8% below its 52-week high of $74.97 from November 2024. Investors who bought $1,000 worth of Independent Bank's shares 5 years ago would now be looking at an investment worth $962.59. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Why Roivant Sciences Stock Bounced Back on Tuesday
Key Points A day after it published its latest set of quarterly earnings, an analyst bumped his price target higher. He also maintained his equivalent of a buy recommendation. 10 stocks we like better than Roivant Sciences › Monday's hangover turned into Tuesday's party for healthcare stock Roivant Sciences (NASDAQ: ROIV). On the back of a modest but meaningful analyst price target hike, investors bid the stock up by nearly 4% following a post-earnings slide the day before. With the Tuesday rise, Roivant handily beat the benchmark S&P 500 index, which bumped 1.1% higher. Boosting the biotech Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his recommendation of outperform (read: buy) on the company's stock. According to reports, Risinger's adjustment is based on a change in his forecast for the biotech company's share count. The analyst based this on management's statements about its share repurchase program, which is expected to shave the tally for shares outstanding. As for Roivant's operations, the pundit waxed bullish on the eventual outcome of the company's phase 3 clinical trial of brepocitinib in the treatment of dermatomyositis, a rare inflammatory disease that can affect the muscles and the skin. He's anticipating a readout of the trial to be published in the second half of this year. A first quarter to forget Risinger's continued bullishness on Roivant was a morale-booster for the market, which had traded out of the company's shares after Monday's fiscal first quarter of 2026 earnings release. The company reported significantly lower revenue compared to the same period of 2025, and it flipped to a net loss on the bottom line. Should you buy stock in Roivant Sciences right now? Before you buy stock in Roivant Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roivant Sciences wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy. Why Roivant Sciences Stock Bounced Back on Tuesday was originally published by The Motley Fool Sign in to access your portfolio
